Skip to content
  • Sunday, 26 July 2026
  • 2:57 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Sobi Receives Complete Response Letter from FDA for Investigational Gout Therapy NASP, Focus on Manufacturing Deficiencies
Pharmaceutical R&D

Sobi Receives Complete Response Letter from FDA for Investigational Gout Therapy NASP, Focus on Manufacturing Deficiencies

Teuku Ryan Jun 30, 2026 0

Swedish Orphan Biovitrum (Sobi) has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning…

Read More
Pharmaceutical R&D

FDA Issues Complete Response Letter to Replimune’s RP1 for Advanced Melanoma

Teuku Ryan Apr 14, 2026 0

The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Replimune Group’s Biologics License Application…

Read More
Europe Faces a Decade-High Surge in Sexually Transmitted Infections, Highlighting Urgent Need for Enhanced Prevention and Treatment StrategiesA Groundbreaking Viral ORFeome Platform Revolutionizes Human Disease Research and Pandemic PreparednessQuantum-Inspired Algorithms Unlock the Potential of Massive Super-Moiré Materials and Topological QuasicrystalsUnlocking the Secrets of Lettuce Pigmentation: Gene Editing Reveals Novel Flavonoid Pathways and Potential for Enhanced Nutrition
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ